stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) Free cash flow
Arcus Biosciences, Inc.'s free cash flow for fiscal 2025 was −$484.0M, compared with −$176.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$465.0M. Over the past ten years it has ranged from −$484.0M (fiscal 2025) to $432.0M (fiscal 2022) — the current reading is the lowest in ten years. Arcus Biosciences, Inc. ranks 589th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$484.0M | — |
| FY2024 | −$176.0M | — |
| FY2023 | −$330.0M | — |
| FY2022 | $432.0M | — |
| FY2021 | −$282.0M | — |
| FY2020 | $108.0M | — |
| FY2019 | −$75.4M | — |
| FY2018 | −$46.7M | — |
| FY2017 | −$30.6M | — |
| FY2016 | −$17.0M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$88.0M | — |
| Jun 2026 | −$119.0M | — |
| Mar 2026 | −$138.0M | — |
| Dec 2025 | −$121.0M | — |
| 36 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| MBX MBX Biosciences, Inc. compare | −$85.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.9M |
| PHVS Pharvaris N.V. compare | −$178.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$196.9M |
| XNCR Xencor, Inc. compare | −$208.3M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$314.5M |
| IDYA IDEAYA Biosciences, Inc. compare | −$349.8M |
| BEAM Beam Therapeutics Inc. compare | −$398.2M |
| RCUS Arcus Biosciences, Inc. | −$465.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on RCUS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement